The approval of Yesintek (ustekinumab-kfce), the sixth biosimilar to reference Stelara, will be used to treat patients with ...

The approval marks the sixth biosimilar to reference Stelara (ustekinumab), and it will be used to treat several immunology ...

The Food and Drug Administration (FDA) has approved Yesintek TM (ustekinumab-kfce), a biosimilar to Stelara ® (Ustekinumab), for the treatment of various chronic inflammatory diseases. Yesintek, ...

Yesintek is the latest Stelara biosimilar to gain FDA approval and it will be available in February 2025.

Both etanercept and ustekinumab have been shown to be strikingly effective in patients with psoriasis. A phase III trial comparing these two biologic agents for the treatment of moderate-to-severe ...

Results of a Phase III study conducted by an international team of researchers reveal that mirikizumab is more effective and ...

A key provision of the Inflation Reduction Act (IRA) of 2022 directed Medicare to negotiate the prices of certain top-selling ...

After filing a new drug submission for its ustekinumab biosimilar PYZCHIVA (Janssen’s STELARA), Samsung commenced the ...

Biocon Biologics has secured USFDA approval to launch the biosimilar of Janssen's Stelara by February 2025, targeting ...

Biocon Biologics Ltd announced today that the U.S. Food and Drug Administration has approved YESINTEK™ (Ustekinumab-kfce), a ...

Mean duration of Crohn's disease was 7.4 years. Nearly half (48.5%) had previous biologic therapy failure, 45.7% had previous ...